Apellis Pharmaceuticals Inc. [NASDAQ: APLS] loss -7.94% on the last trading session, reaching $61.12 price per share at the time. The company report on August 24, 2022 that Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA).
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal).
Apellis Pharmaceuticals Inc. represents 106.63 million in outstanding shares, while the company has a total market value of $6.78 billion with the latest information. APLS stock price has been found in the range of $60.02 to $64.90.
If compared to the average trading volume of 1.05M shares, APLS reached a trading volume of 3525007 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Apellis Pharmaceuticals Inc. [APLS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for APLS shares is $75.94 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on APLS stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Apellis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 19, 2022. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on June 17, 2022, representing the official price target for Apellis Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $40, while ROTH Capital analysts kept a Sell rating on APLS stock.
The Average True Range (ATR) for Apellis Pharmaceuticals Inc. is set at 3.33, with the Price to Sales ratio for APLS stock in the period of the last 12 months amounting to 70.14. The Price to Book ratio for the last quarter was 19.46, with the Price to Cash per share for the same quarter was set at 7.69.
Trading performance analysis for APLS stock
Apellis Pharmaceuticals Inc. [APLS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.99. With this latest performance, APLS shares gained by 9.75% in over the last four-week period, additionally plugging by 46.19% over the last 6 months – not to mention a drop of -0.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for APLS stock in for the last two-week period is set at 50.83, with the RSI for the last a single of trading hit 41.97, and the three-weeks RSI is set at 54.98 for Apellis Pharmaceuticals Inc. [APLS]. The present Moving Average for the last 50 days of trading for this stock 53.71, while it was recorded at 64.59 for the last single week of trading, and 46.91 for the last 200 days.
Apellis Pharmaceuticals Inc. [APLS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Apellis Pharmaceuticals Inc. [APLS] shares currently have an operating margin of -805.67 and a Gross Margin at +97.46. Apellis Pharmaceuticals Inc.’s Net Margin is presently recorded at -1121.27.
Return on Equity for this stock declined to -370.20, with Return on Assets sitting at -81.02.
Apellis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.20 and a Current Ratio set at 7.60.
Apellis Pharmaceuticals Inc. [APLS]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for APLS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Apellis Pharmaceuticals Inc. go to 33.30%.
An analysis of insider ownership at Apellis Pharmaceuticals Inc. [APLS]
There are presently around $5,607 million, or 88.50% of APLS stock, in the hands of institutional investors. The top three institutional holders of APLS stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 11,542,743, which is approximately -18.709% of the company’s market cap and around 1.50% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 9,805,000 shares of the stock with an approximate value of $599.28 million in APLS stocks shares; and VANGUARD GROUP INC, currently with $533.38 million in APLS stock with ownership of nearly 1.839% of the company’s market capitalization.
Positions in Apellis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 136 institutional holders increased their position in Apellis Pharmaceuticals Inc. [NASDAQ:APLS] by around 8,872,893 shares. Additionally, 90 investors decreased positions by around 7,636,207 shares, while 21 investors held positions by with 75,231,982 shares. The mentioned changes placed institutional holdings at 91,741,082 shares, according to the latest SEC report filing. APLS stock had 34 new institutional investments in for a total of 1,231,048 shares, while 33 institutional investors sold positions of 1,212,911 shares during the same period.